Secondary resection in a general mCRC population with cetuximab-based first-line treatment: Interim analysis of the German noninterventional study ERBITAG.
Friedrich Overkamp
No relevant relationships to disclose
Thomas Goehler
No relevant relationships to disclose
Gernot Reich
No relevant relationships to disclose
Michael Schwerdtfeger
No relevant relationships to disclose
Patrick Stuebs
No relevant relationships to disclose
Karsten G Stenzel
Employment or Leadership Position - Merck Serono
Ulf P Neumann
Research Funding - Merck Serono